Trial · NCT07448480
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
NCT07448480, Active not recruiting, Blokhin's Russian Cancer Research Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas. Trials, record NCT07448480. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07448480
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
- NCT number
- NCT07448480
- Status
- Active not recruiting
- Enrollment
- 1,000 participants, actual
- Lead sponsor
- Blokhin's Russian Cancer Research Center
- Conditions
- Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, Pleomorphic Xanthoastrocytoma
- Interventions
- Bevacizumab-Containing Regimens, Non-Bevacizumab Regimens, BRAF ± MEK Targeted Therapy
- First posted
- 2026-03-04
- Last updated
- 2026-03-04
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | From date of initial brain tumor diagnosis until date of death or last contact with the patient, assessed up to 5 years (censored) | Time from the date of initial brain tumor diagnosis to the date of death from any cause or last contact with the patient (censored) |
| Secondary | Progression-Free Survival 1 (PFS1) | From start of chemoradiotherapy until date of first progression or censoring at the start of first-line treatment, assessed up to 5 years | Time from the start of chemoradiotherapy to the date of documented intracranial progression according to RANO 2.0 criteria. Patients who proceeded directly to first-line drug therapy without evidence of progression will be censored at the start of first-line treatment |
| Secondary | Progression-Free Survival 2 (PFS2) | From start of first-line therapy until date of progression or censoring at last instrumental follow-up, assessed up to 5 years | Time from the start of first-line drug therapy to the date of documented intracranial progression according to RANO 2.0 criteria. Patients without documented progression will be censored at the date of last instrumental follow-up (brain MRI or PET-CT with tyrosine/methionine) |
| Secondary | Progression-Free Survival 3 (PFS3) | From start of second-line therapy until date of progression or censoring at last instrumental follow-up, assessed up to 5 years | Time from the start of second-line drug therapy to the date of documented intracranial progression according to RANO 2.0 criteria. Patients without documented progression will be censored at the date of last instrumental follow-up (brain MRI or PET-CT with tyrosine/methionine) |
| Secondary | Progression-Free Survival 4 (PFS4) | From start of third-line therapy until date of progression or censoring at last instrumental follow-up, assessed up to 5 years | Time from the start of third-line drug therapy to the date of documented intracranial progression according to RANO 2.0 criteria. Patients without documented progression will be censored at the date of last instrumental follow-up (brain MRI or PET-CT with tyrosine/methionine) |
| Secondary | Progression-Free Survival 5 (PFS5) | From start of fourth-line therapy until date of progression or censoring at last instrumental follow-up, assessed up to 20 years | Time from the start of fourth-line drug therapy to the date of documented intracranial progression according to RANO 2.0 criteria. Patients without documented progression will be censored at the date of last instrumental follow-up (brain MRI or PET-CT with tyrosine/methionine) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07448480
GET https://conductscience.org/api/trials/v1/NCT07448480/registered